Print Page  Close Window

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$15.85
Change (%) Stock is Up 0.10 (0.63%)
Volume407,266
Data as of 03/24/17 4:00 p.m. ET

Latest News

03/24/17
Paratek Pharmaceuticals Opens New Office in King of Prussia
03/02/17
Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update
02/22/17
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
02/08/17
Paratek Pharmaceuticals, Inc. to Present at LEERINK Partners 6th Annual Global Healthcare Conference
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.